All
FDA Approves Two New Indications for Keytruda in Advanced Melanoma
December 18th 2015The FDA has expanded the approval for single-agent Keytruda to include the frontline treatment of patients with advanced melanoma regardless of BRAF status and to include the treatment of patients with Yervoy-refractory melanoma.